Fluence smoothing evaluation for whole-breast automatically generated treatment plans.

Purpose: This study aimed to identify the fluence smoothing threshold that preserves the dosimetric quality of planning for breast cancer intensity-modulated radiation therapy (IMRT).

Material And Methods: We conducted automated treatment planning for 60 breast cancer patients using the Eclipse Scripting Application Programming Interface. The plans included four-field IMRT, emphasizing smoothing weight combinations while maintaining a 4:3 aspect ratio between the X and Y directions.

Automated treatment planning for whole breast irradiation with individualized tangential IMRT fields.

Purposes: This study aimed to develop and validate algorithms for automating intensity modulated radiation therapy (IMRT) planning in breast cancer patients, with a focus on patient anatomical characteristics.

Material And Methods: We retrospectively selected 400 breast cancer patients without lymph node involvement for automated treatment planning. Automation was achieved using the Eclipse Scripting Application Programming Interface (ESAPI) integrated into the Eclipse Treatment Planning System.

In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus.

Background: To evaluate the in vivo and in vitro toxicity of a new formulation of liposome-encapsulated sirolimus (LES).

Methods: In vitro experiments were done using ARPE-19 and HRP cells. An MTT assay was used to determine cell metabolic activity and a TUNEL assay for detecting DNA fragmentation.

Intravitreal bevacizumab combined with infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: case report series.

Purpose: To evaluate the feasibility of the combined use of bevacizumab (Avastin®) and combined with infliximab (Remicade®) in the treatment of naive choroidal neovascularization due to age-related macular degeneration eyes.

Methods: Intravitreal injections of bevacizumab combined with infliximab in 6 neovascular age-related macular degeneration eyes. All patients underwent complete ophthalmologic examination on the initial visit and at days 1, 30, 60, 90, 120, 150 and 180 following the first injection.

Effects of corneal cross-linking on contrast sensitivity, visual acuity, and corneal topography in patients with keratoconus.

Purpose: To assess the effects of corneal collagen cross-linking (CXL) on contrast sensitivity (CS), visual acuity, and corneal topography investigating possible predictors of efficacy.

Methods: Sixty-eight eyes of 34 patients with progressive keratoconus were enrolled in this prospective study. CXL was performed in one eye and the other eye was left untreated as a control.